Over the course of the past year, we’ve seen renewed interest from federal policymakers in curbing pharmaceutical industry marketing practices that increase drug spending for patients, taxpayers, and the health care system as a whole. This week, the U.S. Department…
I want to tell you a story about one of my patients — let’s call her Helen. After months of treatment, Helen just wasn’t getting better despite being prescribed a drug that I have used to successfully treat many of…
Last month, Institute for Health Policy Director Murray Ross shared a post on Kaiser Permanente’s response to U.S. Department of Health and Human Services’ request for comments on its “Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.”
Over the past couple of decades, pharmaceutical innovation has provided many new treatments for diseases that previously had limited therapeutic options. However, some of these specialty treatments have well documented side effects (known as adverse events) that must be carefully…
Drug companies continue to raise prices to unaffordable levels, making it difficult for patients to access the medication they need to be healthy. This event brought together leaders from across sectors to discuss the drug pricing landscape and elevate effective policy solutions.
